Acrivon bags a megaround to advance an old Eli Lilly program, 5 months after launch. Is an IPO far behind?
Not five months after launching with an old Eli Lilly asset, Acrivon Therapeutics is already upping the ante.
The Cambridge, MA-based biotech pulled in $100 million in a new Series B, aiming to further advance its lead asset and companion platform. And the company has recruited some blue-chip backers for the raise as RA Capital Management and Perceptive Advisors both participated in the round.
Does that mean an IPO is on the horizon? CEO Peter Blume-Jensen won’t rule it out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.